IDEAYA Biosciences, Inc. (IDYA) shares rose 20.98 percent to $36.90, gaining $6.40 on Monday, after the company reported positive topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma.
The stock is currently trading at $36.90, compared to a previous close of $30.50 on the Nasdaq. It opened at $34.92 and has traded in a range of $34.56 to $38.03 during the session, with volume reaching 3.94 million shares versus an average of 935,200 shares.
The company announced that the combination therapy met its primary endpoint, demonstrating a statistically significant improvement in progression free survival, reducing the risk of disease progression by 58 percent compared to standard treatments. The 52-week range for the stock is $15.84 to $39.28.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.